{"name":"Sprout Pharmaceuticals, Inc","slug":"sprout-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Sprout Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing innovative treatments for women's health. The company gained significant attention with its FDA-approved drug, Addyi (flibanserin), for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.","hq":"","founded":0,"employees":"~100","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"flibanserin flexible dose","genericName":"flibanserin flexible dose","slug":"flibanserin-flexible-dose","indication":"Hypoactive sexual desire disorder (HSDD) in premenopausal women","status":"phase_3"}]}],"pipeline":[{"name":"flibanserin flexible dose","genericName":"flibanserin flexible dose","slug":"flibanserin-flexible-dose","phase":"phase_3","mechanism":"Flibanserin is a serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist that modulates neurotransmitter activity in the brain to increase sexual desire.","indications":["Hypoactive sexual desire disorder (HSDD) in premenopausal women"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZFlOVE56VnB2TXZWODRHNGtIN2RpTnVvU1B3T2NRbEozQUJGX2F1WmM2d2tZZXFRUDkyM18zZkg2Y1pfdHY4VlBqMHFaUXV5aUE1TTktMGk4R0wtSWtsNU1VcEM0UU45X0N3a0g2S0s3NmtVV1VYTGZjSlFXbG80UFJZVWZfMU1HeUsyRzhyY1dyZ2Jqc2w1elVvc2lHOGdPREY0ajk5WVk2YS10SVJ3Vg?oc=5","date":"2026-03-06","type":"regulatory","source":"New York Post","summary":"The battle to get ‘female Viagra’ to market — and how ‘Grey’s Anatomy’ played a role - New York Post","headline":"The battle to get ‘female Viagra’ to market — and how ‘Grey’s Anatomy’ played a role","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQbVlMQWNMd1NTMWNOc1dNZ0VwSlRKZ0ZiYWhyYXdGaVpfcjFiLXhTbzk0dUhYN3E0a2RIT1RYWTgtbFdIaVVxMzNxMTdPVXFCaUxKUEtCcU9adUUtVFVsSzJpbDdHOTJyaHNxWUJsamo5TFM5YnhBakN3QXNCUmMyeWJIMTM?oc=5","date":"2026-02-27","type":"pipeline","source":"Drug Channels","summary":"Beyond DTP 2.0: How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences - Drug Channels","headline":"Beyond DTP 2.0: How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNTFkzS01OWHFCU1NSa3V3dEhHLVVQMHNOVzlkaHl4ZmgxaEtrSThOV3Q4ZDZRTzg4bGZtOEZmU1g1dEY3bE90WHBkWFE2TDh6QTN3N0d5NmstN2x2el9QOEhfcnVsdkw0a2lkUlBLaEItaUFNRWlyRExick9PSlBwa1RTOA?oc=5","date":"2025-06-23","type":"regulatory","source":"JD Supra","summary":"FDA Ratchets Enforcement on Social Media Promotion in New Warning Letter - JD Supra","headline":"FDA Ratchets Enforcement on Social Media Promotion in New Warning Letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPZGhkTmcxTlhBdXNVYTJ1YUZTWE1YRFZheFZ1YjBqNjVpbEl3TXdLMmwtSkotTTAta1dvaDhzNmVnSW83c1o3QlhaQjY0dHJhMXZtM0tQcS12LWlQVDg1Q1N4YVpsZkdxZnBNYzBiQm5CNnFGazU5OFk1R0F3X1h4QkMyV1lvQktOYkJBQlktZ0ozZTdDSl9OVVppV09nSFRsdmQ4YlVLRmszanQ4bjRwdTQ0dGZYTVp0clo5b19ORWJuUQ?oc=5","date":"2025-06-12","type":"regulatory","source":"Fierce Pharma","summary":"Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi - Fierce Pharma","headline":"Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQcHpQWXpTRTdtS0tRTlNaWDNicGk1T0ZWcEJONEV3ZDFKSXZBWFc3cDFBeVp2aktLeG5tdVlRcm55NkxZQXlWS1B6N0t6bVo1SHNoRk1lcnBZNy1wNGxudi1mODluZUE4eUkxaFM3cFRISHVsbzU3blhVSDdhd1RxN3BhRUdDazZpVkQzYXQwWnJQNU51LThFSDNWSDhFVzFOLTQ4?oc=5","date":"2025-06-12","type":"regulatory","source":"PharmTech.com","summary":"FDA Posts Slate of Seven Warning Letters Following Company Inspections - PharmTech.com","headline":"FDA Posts Slate of Seven Warning Letters Following Company Inspections","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOVmVnbHpEVEFlYTFZVFQycGo0aFQtbFVTb05DUVNZRTJtWkMtdlctQTNBRzYwT0RlQ3B2NGxmZVF4WFAzTFhtNFBybHNlaEg2Q3ozenBGNktwRERpY05qY2NfUDlnZl92WXhKZ1dXX29za3ZmZjVMeEd2TVpiRXpzaWVKUGF2ZmVkazh3dDdfdkk1clFGRmoyRTJGVnhoRzJwaW13VTJYV0VNWkVRQWZSTG1HdlFYbW0ycDNIOF93XzA3b1NDdkVpeDJPM3NVZHM1UkhwZ3IwM0tVTm1iVGI1U1VSQjVpdjBHSHVxcXpITndVOThTWTluTXAtOHhTOEVlbjgxd3FRSEtSSkc5MFRqS2x6ZDF5b1VfNGgxYmlkYTJFaVN5djZoTnJKMUxscU9XM2ppTGpnYVBrR1A2UHVxcGhCR1hFMUNCRTVsS2RGcw?oc=5","date":"2023-06-02","type":"pipeline","source":"BioSpace","summary":"Sprout Pharmaceuticals Announces Release of Abstract Reporting Positive Interim Results for Flibanserin in Breast Cancer Patients Suffering from Low Libido for Poster Discussion at 2023 ASCO Annual Me","headline":"Sprout Pharmaceuticals Announces Release of Abstract Reporting Positive Interim Results for Flibanserin in Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNUXR4ZWt4c2lpbG1jMldSa3hGanlPSlY0cEFBbWtzQXRSanA0QkRfTTVlOVh3VTFGV0N4OG51UmJ3RGtCSE9waXhWVFdrZDRKMFZqWmhtS3VWU2FyT0tPaU04VjNhREJIWDVSWEJ6ak9hQm9QdlhqWWp5alJJTVRZQlRVTGl0cmQ2SXZjX2phSmtaVnRFNGFMYzZ0NHA3ZG9Jbk5lRDZPcDRmTlU5YlE?oc=5","date":"2017-11-06","type":"regulatory","source":"Genetic Engineering and Biotechnology News","summary":"Valeant Sells \"Female Viagra\" Developer Sprout Pharma Back to Its Shareholders - Genetic Engineering and Biotechnology News","headline":"Valeant Sells \"Female Viagra\" Developer Sprout Pharma Back to Its Shareholders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQckZRWTZ1dV9ldF9IMXRRc19kM3JQclgzTGtlQmF3YTBsWm9rdUpHTDZoOFlEMHFmbjdsVEJlRDNla0N3U0F3X09FTXM4aFNrcVRPYUxJWDZHN1BMakg2SGRPZ0xUQ0RPV0ctX0RiRnJuRHNVQ2kxUkRHNzYzV2MyU2s2ZTRsOGs?oc=5","date":"2017-11-06","type":"pipeline","source":"BioPharma Dive","summary":"Valeant hands Sprout back to former owners - BioPharma Dive","headline":"Valeant hands Sprout back to former owners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNQ19iWUdOQVNNY1VWdHE1Mkp4QjhWZm95TmJFTnpHdkhTNjVsMmYwVUpSYkJXYmtFMnY5M2ZNb2lCaEhQSXpGQk9ybjB1eXRaTVBteFRDQlBJNDZoTVpOTGhOS21sX093WkZOUW9lRkVoV0x5LUU3Y1JyaXlPaGZaR3ZUTy04dmhJQzFpRkU0RTA3QQ?oc=5","date":"2017-11-06","type":"deal","source":"Fierce Pharma","summary":"Valeant admits defeat on Sprout, trading $1B buy for 6% royalty on a drug that's not selling - Fierce Pharma","headline":"Valeant admits defeat on Sprout, trading $1B buy for 6% royalty on a drug that's not selling","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNcmFUUzdUME8yeWRaM05jWDJ0Q3N3SjVHZktmYnpoYkhzZ2NsTzdCTmloRDNCRFZ3cTdpTVdrTXZnb0xUMnRxeHU3c1lsbEZLSEhPV28wVjF4bkt0WDN0eEw2WU9heXVOLWZ5cElhWHYxTEZRVWozN1BmUFJSOW42Ung4OHJqTDFvX09xQzJrbmd3YkFHeVhFS210eGJUMzFxLXg3RUdabXE0QTREcXRpTGh4R1lmM1JXR2FyUGRjOWxWYVo5NWNjQw?oc=5","date":"2015-08-20","type":"regulatory","source":"The New York Times","summary":"Maker of Addyi, ‘Female Viagra’ Drug, Being Sold to Valeant for $1 Billion (Published 2015) - The New York Times","headline":"Maker of Addyi, ‘Female Viagra’ Drug, Being Sold to Valeant for $1 Billion (Published 2015)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQT0Z6UWdzSFpvNlZ0MllNNEpQbUxidkNhRlJIY0FQaXlNRVJzYWNwY0UzX2F1VzE5akUzZjlZRmh0c3ppMUZmSzEtOGl1dTY2NndYTW1HUE9VRUdIdEhDUVlUMWFOdnJHNXdVZzI2c3gwb3hSR3RHMFEwWEx3a1FNZkhxUnBQWW5DRndJ?oc=5","date":"2015-08-20","type":"regulatory","source":"Business Insider","summary":"That was quick: The maker of the first approved women's libido drug was just acquired for $1 billion - Business Insider","headline":"That was quick: The maker of the first approved women's libido drug was just acquired for $1 billion","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPbzFmcFR3enlGX18yLTBmZktsd2JSZ2VtSFFQZldVYldFbVNfMzJFdHlnaEVwMW5JdVhZdFR2Y0s0Z2phdkFEN25QaXdlbm5oR3Q1eFEteE5ra1RXazJEdE43Q3puSUZFN2Utb0phY3FyZWVlNkkybEszVjE5cWFheGtrbld6YUNUQ0FTSVZoUUZ3dmFkS2c?oc=5","date":"2015-08-19","type":"regulatory","source":"Contract Pharma","summary":"Sprout Pharma Receives FDA Approval For ADDYI - Contract Pharma","headline":"Sprout Pharma Receives FDA Approval For ADDYI","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}